Codon Diagnostics
This article was originally published in Start Up
Executive Summary
Codon, a young company developing cancer tests based on organ tissue specific proteins, hopes to have the next PSA test--this time for breast cancer.
You may also be interested in...
Venturing into the Brave New World of Diagnostics Start-Ups
Few diagnostics start-ups are {bona fide} business successes, and that has put a damper on venture capital interest in the field. But this hasn't stopped start-ups trying to meet needs in cancer diagnostics, sample preparation and point-of-care.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.